Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 125 results
A minimalist illustration of a breast and a pathology slide on a solid background.

May 5, 2026

Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Caris Life Sciences has introduced Caris MI Clarity, a groundbreaking AI-powered test aimed at predicting both early and late distant recurrence risks in postmenopausal patients diagnosed with HR-positive/HER2-negative, node-negative early-stage breast cancer. This innovative test promises to deliver results to physicians within three business days, significantly faster than traditional methods.The Caris MI Clarity test utilizes a proprietary dataset comprising thousands of breast cancer samples
A minimalist illustration of a DNA strand on a solid background.

May 4, 2026

Genient Enters Growth Phase with New CEO, Strategic AIT Biotech Partnership

Genient is poised for significant growth as it transitions into a specialized player in clinical genomics and molecular diagnostics, driven by new leadership and strategic partnerships.Founded in 2017 and based in Noida, Genient has evolved from a technology services provider to a focused entity in clinical genomics, aligning its offerings with India's increasing demand for data-driven diagnostics. The company targets critical areas such as infectious diseases, antimicrobial resistance, oncology
A genomic sample in a petri dish on a lab bench

May 4, 2026

Genient Charts New Path with Landmark Partnership in Genomic Diagnostics

Genient is embarking on a transformative journey in genomic diagnostics through a significant partnership with AIT Biotech, aimed at addressing the growing demand for advanced healthcare solutions in India.Based in Noida, Genient is enhancing its strategic direction under the leadership of Mr. Anil Kumar and newly appointed CEO Mr. Brijesh Singh. This partnership with AIT Biotech, located in Singapore, marks a pivotal shift for the company as it moves from technology services to a concentrated f
A minimalist representation of a liquid biopsy tube and a biomarker icon in flat design.

May 3, 2026

Guardant Health Partners with Nuvalent to Advance Precision Oncology

Guardant Health is entering a strategic partnership with Nuvalent to enhance precision oncology through improved biomarker-driven drug development.This collaboration aims to optimize patient selection and streamline clinical trials by integrating Guardant’s Infinity platform with Nuvalent’s oncology pipeline. By utilizing both tissue and liquid biopsy solutions, the partnership intends to refine the identification of patient populations suitable for targeted cancer therapies.As part of this init
A minimalist representation of a CAR-T cell and lymphocyte in a dark palette.

May 2, 2026

Is Growing Focus On CAR-T Data And CARVYKTI Orders Reframing Legend Biotech’s (LEGN) Investment Story?

Legend Biotech is increasingly in the spotlight as analysts focus on its CAR-T pipeline and the strength of CARVYKTI orders, particularly with upcoming clinical data readouts on the horizon.The company recently participated in the Cell & Gene Meeting on the Mediterranean and is set to discuss its first-quarter 2026 results in an upcoming investor call. Analysts are optimistic about Legend's CAR-T developments, linking the strong order book for CARVYKTI to anticipated clinical updates. This creat
A blood droplet and heart silhouette representing cardiovascular diagnostics.

May 2, 2026

Cardio Diagnostics Advances Early Detection of Heart Disease Using AI and Biomarkers

Cardio Diagnostics Holdings is leveraging artificial intelligence and biomarker analysis to enhance the early detection of cardiovascular disease, a leading cause of death globally.The company’s innovative platform utilizes a blood sample to provide personalized cardiovascular insights, merging genetic and epigenetic biomarkers with AI technology. This approach is particularly timely given the pressing need for effective solutions to combat cardiovascular disease, which significantly impacts ind
A blood pressure cuff and stethoscope in a clinical setting

May 1, 2026

Cardio Diagnostics Holdings (CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights

Cardio Diagnostics Holdings (CDIO) is taking significant steps to combat heart disease by leveraging AI and biomarker analysis for early detection and personalized insights.Cardiovascular disease remains a critical global health issue, imposing severe burdens on individuals and healthcare systems alike. Cardio Diagnostics Holdings aims to mitigate this impact by developing a platform that utilizes artificial intelligence alongside epigenetic and genetic biomarkers. This innovative approach allow
A flat design of a blood droplet and biomarker icon representing cardiovascular diagnostics.

May 1, 2026

Cardio Diagnostics Holdings (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights

Cardio Diagnostics Holdings is leveraging artificial intelligence and biomarker analysis to enhance early detection of cardiovascular disease, a leading global health concern.The burden of cardiovascular disease is significant, affecting millions and imposing heavy costs on healthcare systems. Cardio Diagnostics Holdings (NASDAQ: CDIO) is addressing this urgent need by developing a unique platform that integrates AI with multi-omic biomarker analysis. This innovation aims to provide personalized
A minimalist illustration of a retina and circular RNA strand for Alzheimer's detection.

Apr 30, 2026

Circular Genomics and Vitazi.ai Forge Strategic Alliance to Develop First-in-Class Multimodal Workflow for Early Alzheimer's Detection

Circular Genomics and Vitazi.ai have announced a strategic partnership aimed at revolutionizing early Alzheimer's disease detection through a multimodal workflow that integrates AI-powered retinal imaging with circular RNA biomarkers.This collaboration seeks to address significant gaps in the current diagnostic landscape for Alzheimer's, where many patients are diagnosed only after symptoms have progressed. The new approach combines non-invasive retinal imaging analytics from Vitazi.ai with Circ
A minimalist representation of retinal imaging and RNA biomarkers for Alzheimer's detection.

Apr 29, 2026

New Partnership Aims to Improve Early Alzheimer’s Disease Detection

A strategic partnership between Circular Genomics and Vitazi.ai aims to enhance early detection of Alzheimer’s disease through innovative diagnostic technologies.The collaboration seeks to merge artificial intelligence-driven retinal imaging with blood-based RNA biomarkers to identify individuals at risk for Alzheimer’s. This partnership addresses existing gaps in early-stage patient identification and aims to create a comprehensive diagnostic framework.The proposed workflow involves a two-step
Flat illustration of a DNA strand and AI molecule

Apr 29, 2026

$2.25 Billion DNA Editing Deal Signals Why AI Training Is Becoming Essential in Biotech

The recent $2.25 billion partnership between Profluent and Eli Lilly underscores the growing importance of AI in biotechnology, particularly in the realm of DNA editing.This collaboration aims to develop AI-designed recombinases—enzymes capable of precisely altering larger DNA sequences, addressing complex genetic diseases that traditional editing methods struggle to treat. By harnessing AI, the partnership seeks to enhance treatment options for rare diseases and inherited disorders, potentially
A test tube with a colorful liquid on a lab bench, symbolizing genetic medicine.

Apr 29, 2026

Profluent, Eli Lilly Strike $2.25B AI-Driven Genetic Medicine Pact for Precision DNA Editing

Profluent and Eli Lilly have entered a significant multi-program collaboration valued at up to $2.25 billion, focusing on advanced AI-driven genetic medicine aimed at precision DNA editing.The partnership centers around Profluent's innovative use of AI to develop recombinases, which are enzymes designed for kilobase-scale DNA editing. This technology is particularly important for addressing genetic diseases characterized by multiple mutations, a challenge that traditional methods like CRISPR str